Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00470704 2024-12-19

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Phase 2 Completed

87 enrolled 23 charts

Breast

Breast Neoplasms

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Phase 2 Completed

647 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT01622868 2023-10-17

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Phase 2 Completed

143 enrolled 24 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01711658 2023-10-17

TRYHARD

Phase 2 Completed

142 enrolled 22 charts

Head & Neck

Head and Neck Neoplasms

NCT00841828 2023-03-31

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Phase 2 Completed

102 enrolled 10 charts

Breast

Breast Neoplasms

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2 Completed

122 enrolled 22 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT00444535 2021-10-25

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Phase 2 Completed

52 enrolled 13 charts

Breast

Breast Neoplasms, Osteitis Deformans

NCT00206427 2021-09-29

GW

Phase 2 Completed

49 enrolled 7 charts

Breast

Breast Neoplasms, Neoplasms

NCT02073487 2021-09-22

TEAL

Phase 2 Completed

32 enrolled 7 charts

Breast

Breast Neoplasms

NCT00883688 2020-08-26

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Phase 2 Completed

24 enrolled 5 charts

CNS

Brain Neoplasms, Ependymoma, Neuroectodermal Tumors, Primitive, Glioma, Subependymal

NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Phase 2 Completed

159 enrolled

Breast

HER2 Positive Breast Cancer

NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2 Completed

64 enrolled 13 charts

Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

NCT01044433 2020-03-19

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Phase 2 Completed

44 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT00939523 2020-01-22

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Phase 2 Completed

9 enrolled 11 charts

Endocrine

Pituitary Neoplasms, Prolactinoma

NCT00574171 2019-12-18

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

Phase 2 Completed

29 enrolled 6 charts

Gastrointestinal

Colorectal Neoplasms

NCT01827163 2019-12-18

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Phase 2 Completed

20 enrolled 8 charts

Breast

HER2-Positive Early Stage Breast Cancer

NCT00263588 2019-12-12

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Phase 2 Completed

242 enrolled 19 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms

NCT00548184 2019-11-07

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Phase 2 Completed

65 enrolled 5 charts

Breast

Breast Neoplasms

NCT00820872 2019-10-21

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Phase 2 Completed

30 enrolled 6 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00096447 2019-07-24

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

31 enrolled 13 charts

Gynecologic

Endometrial Neoplasms

NCT00113373 2019-07-24

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Phase 2 Completed

28 enrolled 11 charts

Gynecologic

Carcinoma, Ovarian Epithelial

NCT00826241 2019-03-22

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

Phase 2 Completed

58 enrolled 11 charts

CNS

Brain Neoplasms, Ependymoma, Spinal Cord Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

50 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT00320411 2019-01-31

GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer

Phase 2 Completed

62 enrolled 24 charts

Breast

Breast Neoplasms

NCT01973660 2018-09-19

PAMELA

Phase 2 Completed

151 enrolled

Breast

Breast Neoplasms

NCT00477464 2018-09-17

Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Phase 2 Completed

51 enrolled 25 charts

Breast

Breast Neoplasms

NCT00777101 2018-08-09

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Phase 2 Completed

233 enrolled 16 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01485926 2018-08-06

TCHL Phase II

Phase 2 Completed

120 enrolled

Breast

Breast Neoplasms

NCT00107003 2018-07-05

GW572016 to Treat Recurrent Malignant Brain Tumors

Phase 2 Completed

9 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Gliosarcoma

NCT00101036 2018-04-20

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

57 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT02015169 2018-01-17

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

Phase 2 Completed

32 enrolled

Gastrointestinal

Stomach Neoplasms

NCT00404066 2017-12-22

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Phase 2 Completed

21 enrolled 11 charts

Breast

Breast Neoplasms

NCT00118157 2017-12-04

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Phase 2 Completed

19 enrolled 6 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02338245 2017-10-17

Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab

Phase 2 Completed

200 enrolled

Breast

Breast Neoplasms

NCT01688609 2017-09-11

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

Phase 2 Completed

18 enrolled 7 charts

Breast

Breast Neoplasms

NCT01275859 2017-08-29

Neo-All-In

Phase 2 Completed

25 enrolled

Breast

Breast Neoplasms

NCT00721630 2017-08-15

Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer

Phase 2 Completed

24 enrolled 8 charts

Breast

Breast Neoplasms

NCT00246753 2017-06-28

NRR

Phase 2 Completed

29 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT00111787 2017-05-31

Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

Phase 2 Completed

49 enrolled

Breast

Breast Neoplasms

NCT01013740 2017-05-31

VITAL

Phase 2 Completed

112 enrolled 15 charts

Breast

Breast Neoplasms, Neoplasms

NCT00482391 2017-05-12

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2 Completed

95 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00095563 2017-04-18

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

Phase 2 Completed

40 enrolled 9 charts

Head & Neck

Salivary Gland Neoplasms

NCT00089999 2017-02-28

Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

Phase 2 Completed

138 enrolled 16 charts

Breast

Breast Neoplasms

NCT02342587 2017-02-17

Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

Phase 2 Completed

7 enrolled

HER2-positive Refractory Advanced Cancer

NCT00524303 2016-11-11

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Phase 2 Completed

100 enrolled 14 charts

Breast

Breast Neoplasms

NCT00422903 2016-05-12

Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer

Phase 2 Completed

92 enrolled 14 charts

Breast

Breast Neoplasms

NCT00429299 2016-03-22

CHERLOB

Phase 2 Completed

121 enrolled 16 charts

Breast

Breast Neoplasms

NCT00973739 2016-03-22

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Phase 2 Completed

21 enrolled 8 charts

CNS

Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

NCT00347919 2016-02-25

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Phase 2 Completed

189 enrolled 15 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

Clinical Trials

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

TRYHARD

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Lapatinib and Bevacizumab for Metastatic Breast Cancer

GW

TEAL

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

MetAction

GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer

PAMELA

Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

TCHL Phase II

GW572016 to Treat Recurrent Malignant Brain Tumors

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

Neo-All-In

Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer

NRR

Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

VITAL

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer

CHERLOB

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer